



PRESS RELEASE

PIERREL IN NORTH AMERICA

GOCCLES FINALIST TO THE EDISON AWARDS 2019

Capua, 12 February 2019 - **Pierrel Pharma Srl** ("Pierrel Pharma" or the "Company") - a wholly owned subsidiary of **Pierrel SpA** and devoted to the development, registration and licensing of new drugs and medical devices - announces that its diagnostic device GOCCLES has been named a finalist in the Medical/Dental category and the Diagnostic subcategory in the 2019 Edison Awards.

The Edison Awards, named after Thomas Alva Edison, recognizes and honors the world's best in innovators and innovations. The Edison Awards will announce gold, silver and bronze award winners at the Edison Awards Gala held on Thursday, April 4, 2019 in New York City.

The GOCCLES device consists of eyewear fitted with patented optical filters that when used with a common curing light allows an autofluorescence visualization of the oral cavity to detect oral abnormalities such as dysplastic or anaplastic lesions. It has been developed and patented at the Catholic University of Rome and is owned by Pierrel Pharma.

Says Fabio Velotti, Director of the Company "This is a first important recognition for the strong content of sustainability, both of use and costs, full izio serve the prevention malatti and oral cavity. In order to be used, in fact, GOCCLES needs an unsophisticated light source, such as lamps photopolymerizers already present in all dental practices. M above all, no n is invasative for the patient and allows a scre and ning in just 60 seconds . "

GOCCLES, like all nominations, were reviewed by the Edison Awards Steering Committee and the final ballot was sent to an independent judging panel. The judging panel was comprised of more than 3,000 professionals from the fields of product development, design engineering, science, marketing and education including professional organizations representing a wide variety of industries and disciplines

The Edison Awards were established in 1987, The Edison Awards is a program led conducted by Edison Universe, a non-profit 501 ©(3) organization dedicated to fostering future innovators. For more information on the 2019 Edison Awards www.edisonawards.com .



Pierrel SpA specializes in the production of pharmaceutical specialties (*Division Contract Manufacturing*) and in the development, registration and *licensing* of new drugs and medical devices (*Division and Pharma*).

The Pierrel Group - listed on the merca to MTA-organized, oeg estito Italian Stock Exchange - has over 60 years in the pharmaceutical sector and is one of the leading European manufacturers of local and dental anesthetics.

Pierrel owns a production plant in Capua, in Naples (Italy), which received authorization from the EMA ("*European Medicines Agency*") and the FDA ("*Food and Drug Administration*") for the aseptic production of injectable drugs.

Pierrel Pharma Srl (wholly owned by Pierrel SpA) has registered and distributes the dental anestheticl Orabloc® in Canada, USA, Russia and Europe and the Goccles® medical device in the USA, Canada and Europe

The registered office of Pierrel SpA is in Capua (CE), Italy.

For more information:

Pierrel SpA

Investor Relator

Dott. Fulvio Citaredo

Email: investor.relations@pierrelgroup.com

tel. +39 0823 626 111

fax +39 0823 626 228

Global Consult Srl

Media Relations

Rossana Del Forno

E-mail: areacomunicazione@globalconsultsrl.com

tel. +39 333 6178665

1



2